Mumbai, Aug. 10 -- REVAHALE is the first and only once-daily LAMA available in India that combines once-daily dosing with nebulised administration, offering a treatment option for COPD patients who require nebulised therapy.

The company said the therapy is designed to provide sustained 24-hour bronchodilation through a single daily dose. It is intended to address challenges associated with inhaler-based therapies, particularly among elderly patients and those with severe respiratory impairment.

COPD is a major public health challenge in India and a leading cause of morbidity and mortality. According to the company, some patients face difficulties using handheld inhalers due to cognitive limitations, severe breathlessness or an inability...